EGFR-mediated intracellular delivery of Pc 4 nanoformulation for targeted photodynamic therapy of cancer: in vitro studies.

UNLABELLED In photodynamic therapy (PDT), the light activation of a photosensitizer leads to the generation of reactive oxygen species that can trigger various mechanisms of cell death. Harnessing this process within cancer cells enables minimally invasive yet targeted cancer treatment. With this rationale, here we demonstrate tumor-targeted delivery of a highly hydrophobic photosensitizer Pc 4 loaded within biocompatible poly(ethylene glycol)-poly(ɛ-caprolactone) block co-polymer micelles. The micelles were surface-modified with epidermal growth factor receptor (EGFR)-targeting GE11 peptides for active targeting of EGFR-overexpressing cancer cells, in vitro. Pc 4-loaded EGFR-targeted micelles were incubated with EGFR-overexpressing A431 epidermoid carcinoma cells for various time periods, to determine Pc 4 uptake by epifluorescence microscopy. The cells were subsequently photoirradiated, and PDT-induced cell death for various incubation periods was determined by MTT assay and fluorescence Live/Dead assay. Our results indicate that active EGFR targeting of the Pc 4-loaded micelles accelerates intracellular uptake of the drug. Consequently, this enhances the PDT-induced cytotoxicity within shorter time periods. FROM THE CLINICAL EDITOR Photodynamic cancer therapy using Pc 4, a light activated and highly hydrophobic photosensitizer is demonstrated in this paper in vitro. Pc 4 was delivered in block-copolymer micelles surface-modified with GE11 peptides targeting EGFR-overexpressing cancer cells.

[1]  J. V. van Lier,et al.  Targeted photodynamic therapy via receptor mediated delivery systems. , 2004, Advanced drug delivery reviews.

[2]  T. Reimer,et al.  Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life. , 2010, Deutsches Arzteblatt international.

[3]  C. Allen,et al.  Epidermal growth factor-conjugated poly(ethylene glycol)-block- poly(delta-valerolactone) copolymer micelles for targeted delivery of chemotherapeutics. , 2006, Bioconjugate chemistry.

[4]  H. Klok,et al.  Advanced drug delivery devices via self-assembly of amphiphilic block copolymers. , 2001, Advanced drug delivery reviews.

[5]  E. Zuhowski,et al.  Plasma pharmacokinetics and tissue distribution in CD2F1 mice of Pc4 (NSC 676418), a silicone phthalocyanine photodynamic sensitizing agent , 1999, Cancer Chemotherapy and Pharmacology.

[6]  Baowei Fei,et al.  Highly efficient drug delivery with gold nanoparticle vectors for in vivo photodynamic therapy of cancer. , 2008, Journal of the American Chemical Society.

[7]  D. Maysinger,et al.  Cellular internalization of PCL(20)-b-PEO(44) block copolymer micelles. , 1999, Biochimica et biophysica acta.

[8]  Kevin D Cooper,et al.  Photodynamic therapy with the phthalocyanine photosensitizer Pc 4: the case experience with preclinical mechanistic and early clinical-translational studies. , 2007, Toxicology and applied pharmacology.

[9]  S. Barni,et al.  Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel , 2010, Expert opinion on pharmacotherapy.

[10]  J. Vermorken,et al.  Targeted therapies in head and neck cancer: past, present and future. , 2008, Reviews on recent clinical trials.

[11]  R. Donehower,et al.  Drug therapy : paclitaxel (Taxol) , 1995 .

[12]  Marilena Loizidou,et al.  Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. , 2009, Trends in pharmacological sciences.

[13]  Brian W Pogue,et al.  Tumor PO(2) changes during photodynamic therapy depend upon photosensitizer type and time after injection. , 2002, Comparative biochemistry and physiology. Part A, Molecular & integrative physiology.

[14]  T J Dougherty,et al.  Photoradiation therapy. II. Cure of animal tumors with hematoporphyrin and light. , 1975, Journal of the National Cancer Institute.

[15]  Melinda Fitzgerald,et al.  Immunol. Cell Biol. , 1995 .

[16]  J Verweij,et al.  Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. , 2001, European journal of cancer.

[17]  P. Baldrick Pharmaceutical excipient development: the need for preclinical guidance. , 2000, Regulatory toxicology and pharmacology : RTP.

[18]  Indrajit Roy,et al.  Organically modified silica nanoparticles with covalently incorporated photosensitizer for photodynamic therapy of cancer. , 2007, Nano letters.

[19]  Peter K. Kik,et al.  Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD) , 1999, British Journal of Cancer.

[20]  H. Uludaǧ,et al.  Conjugation of arginine-glycine-aspartic acid peptides to poly(ethylene oxide)-b-poly(epsilon-caprolactone) micelles for enhanced intracellular drug delivery to metastatic tumor cells. , 2007, Biomacromolecules.

[21]  T. Foster,et al.  Irradiation‐Induced Enhancement of Pc 4 Fluorescence and Changes in Light Scattering are Potential Dosimeters for Pc 4‐PDT † , 2007, Photochemistry and photobiology.

[22]  T. Allen,et al.  Lipid-derivatized poly(ethylene glycol) micellar formulations of benzoporphyrin derivatives. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[23]  Ming Yao,et al.  Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  C. Sibata,et al.  Photosensitizers in clinical PDT. , 2004, Photodiagnosis and photodynamic therapy.

[25]  L. Dubertret,et al.  INTERACTION OF HUMAN SERUM LOW DENSITY LIPOPROTEINS WITH PORPHYRINS: A SPECTROSCOPIC AND PHOTOCHEMICAL STUDY , 1984, Photochemistry and photobiology.

[26]  Christine Allen,et al.  Nano-engineering block copolymer aggregates for drug delivery , 1999 .

[27]  Jean-François Gohy,et al.  Block copolymer micelles , 2005 .

[28]  Zonghai Li,et al.  Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. , 2008, International journal of pharmaceutics.

[29]  A. S. Sobolev,et al.  Targeted intracellular delivery of photosensitizers to enhance photodynamic efficiency , 2000, Immunology and cell biology.

[30]  Zhuang Liu,et al.  Folate-conjugated crosslinked biodegradable micelles for receptor-mediated delivery of paclitaxel , 2011 .

[31]  J. Verweij,et al.  Pharmacological Effects of Formulation Vehicles , 2003, Clinical pharmacokinetics.

[32]  Vladimir P Torchilin,et al.  Passive and active drug targeting: drug delivery to tumors as an example. , 2010, Handbook of experimental pharmacology.

[33]  D. Maysinger,et al.  Block copolymer micelles as delivery vehicles of hydrophobic drugs: Micelle–cell interactions , 2006, Journal of drug targeting.

[34]  Cornelus F. van Nostrum,et al.  Polymeric micelles to deliver photosensitizers for photodynamic therapy. , 2004 .

[35]  N. Nishiyama,et al.  Design and development of dendrimer photosensitizer-incorporated polymeric micelles for enhanced photodynamic therapy. , 2009, Advanced drug delivery reviews.

[36]  Kashif Azizuddin,et al.  The Peripheral Benzodiazepine Receptor in Photodynamic Therapy with the Phthalocyanine Photosensitizer Pc 4¶ , 2002, Photochemistry and photobiology.

[37]  Lawrence X. Yu,et al.  In vitro and in vivo characterizations of PEGylated liposomal doxorubicin. , 2011, Bioanalysis.

[38]  H. Fearnhead Getting Back on Track, or what to do when apoptosis is de-railed: Recoupling Oncogenes to the Apoptotic Machinery , 2004, Cancer biology & therapy.

[39]  R. Singal,et al.  EGFR targeting of solid tumors. , 2007, Cancer control : journal of the Moffitt Cancer Center.

[40]  P. Morlière,et al.  Photodynamic therapies: principles and present medical applications. , 2006, Bio-medical materials and engineering.

[41]  Allan S. Hoffman,et al.  The origins and evolution of "controlled" drug delivery systems. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[42]  Xia Han,et al.  Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity , 2004, Molecular Cancer.

[43]  Nancy L Oleinick,et al.  The role of apoptosis in response to photodynamic therapy: what, where, why, and how , 2002, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[44]  G. Tortora,et al.  Rational bases for the development of EGFR inhibitors for cancer treatment. , 2007, The international journal of biochemistry & cell biology.

[45]  Kshirsagar Drug delivery systems , 2000 .

[46]  Yechezkel Barenholz,et al.  Pharmacokinetics of Pegylated Liposomal Doxorubicin , 2003, Clinical pharmacokinetics.

[47]  I. Tan,et al.  Photodynamic therapy in the treatment of multiple primary tumours in the head and neck, located to the oral cavity and oropharynx , 2007, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.

[48]  Myriam E. Rodriguez,et al.  Delivery of the photosensitizer Pc 4 in PEG-PCL micelles for in vitro PDT studies. , 2010, Journal of pharmaceutical sciences.

[49]  T. Hasan,et al.  Targeted photodynamic therapy , 2006, Lasers in surgery and medicine.

[50]  Alexander Gaitanis,et al.  Liposomal doxorubicin and nab-paclitaxel: nanoparticle cancer chemotherapy in current clinical use. , 2010, Methods in molecular biology.

[51]  Roy S Herbst,et al.  Monoclonal antibodies to target epidermal growth factor receptor–positive tumors , 2002, Cancer.

[52]  Vladimir P. Torchilin,et al.  Enhanced in vivo antitumor efficacy of poorly soluble PDT agent, meso-tetraphenylporphine, in PEG-PE-based tumor-targeted immunomicelles , 2007, Cancer biology & therapy.